Researchers recently conducted a comprehensive study on thymic epithelial tumours to better understand their complex tumour microenvironment (TME). These rare thoracic malignancies exhibit significant heterogeneity, ranging from indolent thymomas to highly aggressive thymic carcinomas (TC). Consequently, clinicians often face challenges in prognostic assessment and treatment stratification. By analyzing tissue samples and genetic data from multiple cohorts, the research team identified distinct genetic relationships and metabolic activities across World Health Organization (WHO) subtypes.

The TME of Aggressive Thymic Epithelial Tumours

The study's mutation tree analysis demonstrated clear evolutionary divergence among the various histological subtypes. Specifically, type B3 thymomas and thymic carcinomas were the most genetically distinct. These aggressive subtypes cluster together due to their shared malignant potential and poorer clinical outcomes. In contrast, type A and AB thymomas showed closer genetic proximity, reflecting their typically indolent behavior. Furthermore, the profiling effort identified three main TME clusters that align with these clinical characteristics, providing a clearer biological framework for the disease.

Moreover, the metabolic landscape of these tumours reveals critical insights into their progression. Patients with TC or type B3 thymoma showed significantly enhanced amino acid and fatty acid metabolism. Additionally, these aggressive subtypes exhibited high levels of macrophage infiltration and reduced numbers of resting dendritic cells. Immunohistochemistry confirmed that biomarkers like CD68, GLS2, and ARG2 are overexpressed in these high-risk cases. Therefore, these immunometabolic markers could serve as vital tools for future personalised therapy in aggressive malignancies.

Frequently Asked Questions

Which metabolic pathways are most active in aggressive thymic epithelial tumours?

Aggressive subtypes, particularly thymic carcinoma and type B3 thymomas, show enhanced amino acid and fatty acid metabolism. These metabolic shifts support the high energy demands and rapid growth characteristic of malignant tumours.

What are the primary immunometabolic biomarkers for aggressive TETs?

The study identifies CD68, GLS2, and ARG2 as key biomarkers for aggressive subtypes. These markers reflect increased macrophage infiltration and altered metabolic activity, providing potential targets for prognostic assessment and treatment stratification.

Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Liu W et al. Characterization of tumour microenvironment in thymic epithelial tumours of different histological subtypes. Discov Oncol. 2026 Feb 15. doi: 10.1007/s12672-026-04618-9. PMID: 41691589.


2. Girard N, et al. Thymic epithelial tumours: ESMO–EURACAN Clinical Practice Guidelines. Ann Oncol. 2020;31(11):1478-1491.


3. Marx A, et al. The 2021 WHO Classification of Tumors of the Thymus and Mediastinum. J Thorac Oncol. 2022;17(2):200-217.